Streetbeat News

Regulatory

CHPT

SIEGY

ChargePoint and Siemens are key players in the clean tech revolution, focusing on EV infrastructure and eVTOL technology. ChargePoint is enhancing EV charging with AI and power-sharing, while Siemens plans to spin off its EV charging business. The eVTOL industry is poised for growth with upcoming FAA regulations.

Portfolio Pulse from Surbhi Jain

September 30, 2024 | 2:21 pm

EBS

California Governor Gavin Newsom signed a bill requiring naloxone, a medication that can reverse opioid overdoses, to be included in workplace first aid kits. The bill, Assembly Bill 1976, mandates California regulators to draft rules for this requirement by December 2028. The move aims to increase naloxone accessibility and reduce opioid-related deaths. The bill faced initial opposition from construction industry groups but was amended to require only consideration of the proposal, not a mandate.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:12 pm

SPRC

SciSparc has received FDA approval to begin a pivotal Phase IIb trial for its Tourette Syndrome treatment, SCI-110, in the U.S. This follows promising Phase IIa results showing up to 40% reduction in tics.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:27 pm

AXDX

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has received FDA clearance for its Accelerate Arc system, an automated platform for rapid microbial identification, enhancing the fight against sepsis and antimicrobial resistance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:16 pm

MNOV

MediciNova, Inc. (NASDAQ:MNOV) has announced a $22 million grant from the NIH to evaluate the efficacy of MN-166 in treating ALS through an Expanded Access Protocol. This trial will provide access to the drug for ALS patients not eligible for the COMBAT-ALS trial.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:05 pm

GEVO

Gevo has received a notification from Nasdaq confirming its compliance with the listing rule as of September 27. This ensures that Gevo remains listed on the Nasdaq exchange.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:05 pm

MBOT

Microbot Medical has accelerated the enrollment rate in its ACCESS-PVI trial, with 80% of patients having completed the follow-up period. The company is on track for an FDA 510(k) submission by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:35 pm

ANIX

Anixa Biosciences has submitted an amendment to its CAR-T trial protocol, allowing a second dose of CAR-T therapy for suitable patients. This development could enhance treatment efficacy and patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

GRI

GRI Bio has been granted a patent in Japan for a treatment related to inflammatory conditions, which could enhance its intellectual property portfolio and potentially lead to new market opportunities.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:32 pm

KAVL

Delta Corp Holdings is advancing its business combination with Kaival Brands by submitting a draft registration statement to the SEC. This move will create a new publicly listed holding company.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:32 pm